Showing results (131-140 of 157) with videos related to
Sort By:
Pageof 16
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 27, 2011
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomesPartow Kebriaei, Rima Saliba, Gabriela Rondon, et al.Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.Blood|January 10, 2016
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Audrey V Lamb, Susan O'Brien, et al.British Journal of Haematology|April 3, 2004
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeMaha M T El-Zimaity, Hagop Kantarjian, Moshe Talpaz, et al.Clinical Lymphoma & Myeloma|September 1, 2009
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimensJennifer L Kelly, Stephen R Toothaker, Lauren Ciminello, et al.The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.American Journal of Hematology|January 5, 2017
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remissionNaveen Pemmaraju, Hagop Kantarjian, Jeffrey L Jorgensen, et al.Blood|April 13, 2006
Lenalidomide therapy in myelofibrosis with myeloid metaplasiaAyalew Tefferi, Jorge Cortes, Srdan Verstovsek, et al.Pageof 16